Nearly uniform failure of atrial flutter ablation and continuation of antiarrhythmic agents (hybrid therapy) for the long-term control of atrial fibrillation

摘要

Background Ablation for atrial flutter and continued pharmacologic therapy (hybrid therapy) is a management strategy when treatment with class I antiarrhythmic drugs organize atrial fibrillation (AF) into flutter. Previous studies with 2–3-year follow-up have reported satisfactory control of AF burden.